Current as of December 10, 2023
Background: It may be in the interest of the CCR to continue to follow and treat certain subjects after they have completed their treatment and participation on a research protocol. Objective: To provide continuing treatment and medical follow-up for CCR subjects who have completed their treatment and participation on a research protocol and who are not currently entered on or eligible for another active research protocol. Eligibility: Subjects who have been previously enrolled on and received treatment according to an approved CCR research protocol. (clinical trial) It is in the best...
- INCLUSION CRITERIA:
- Subjects of any age who have been previously enrolled and treated on an approved CCR research treatment protocol.
- It is in the best interests of the subject and the CCR for the subject to continue to receive treatment and follow-up at the NIH.
- The subject or guardian signs the informed consent and agrees to the proposed treatment regimen.
- EXCLUSION CRITERIA:
- Subjects who have not been previously treated on a CCR research treatment protocol.
- Subjects who are receiving an investigational therapy.
The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, Maryland, United States
All reviews come from applied patients